Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

被引：4

作者：

Soumerai, Jacob D. ^{[1
]}

Diefenbach, Catherine S. ^{[2
]}

Samaniego, Felipe ^{[3
]}

Kumar, Abhijeet ^{[4
]}

Tsai, Michaela L. ^{[5
]}

Asch, Adam S. ^{[6
]}

Jagadeesh, Deepa ^{[7
]}

Kenkre, Vaishalee P. ^{[8
]}

Lossos, Izidore S. ^{[9
]}

Salman, Huda ^{[10
]}

Awan, Farrukh T. ^{[11
]}

Miao, Lu ^{[12
]}

Ghalie, Richard G. ^{[12
]}

Zelenetz, Andrew D. ^{[13
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Lymphoma, Boston, MA 02114 USA

[2] NYU, Sch Med, NYU Canc Inst, New York, NY USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[4] Univ Arizona, Ctr Canc, Div Hematol & Oncol, Tucson, AZ USA

[5] Swedish Canc Inst, Seattle, WA USA

[6] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA

[7] Cleveland Clin Fdn, Taussig Canc Inst, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA

[8] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[9] Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL USA

[10] Stony Brook Univ Hosp, Stony Brook, NY USA

[11] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[12] MEI Pharma Inc, San Diego, CA USA

[13] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-157563

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up
Song, Yuqin
Zhou, Keshu
Li, Dengju
Hu, Jianda
Zou, Dehui
Gao, Sujun
Yang, Haiyan
Zhang, Huilai
Ji, Jie
Xu, Wei
Feng, Ru
Jin, Jie
Lyu, Fangfang
Fang, Cheng
Xu, Sheng
Zhu, Jun
BLOOD, 2023, 142
[22] Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma
Dreyling, Martin H.
Santoro, Armando
Leppa, Sirpa
Demeter, Judit
Follows, George
Lenz, Georg
Kim, Won Seog
Mollica, Luigina
Nagler, Arnon
Diong, Colin Phipps
Provencio, Mariano
Magagnoli, Massimo
Radinoff, Atanas
Munoz, Javier
Cao, Anjun
Hiemeyer, Florian
Odongo, Fatuma
Garcia-Vargas, Jose E.
Childs, Barrett H.
Zinzani, Pier Luigi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[23] Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
Till, Kathleen J.
Abdullah, Mariah
Alnassfan, Tahera
Janet, Gallardo Zapata
Marks, Thomas
Coma, Silvia
Weaver, David T.
Pachter, Jonathan A.
Pettitt, Andrew R.
Slupsky, Joseph R.
SCIENTIFIC REPORTS, 2023, 13 (01)
[24] PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
Yahiaoui, Anella
Meadows, Sarah A.
Sorensen, Rick A.
Cui, Zhi-Hua
Keegan, Kathleen S.
Brockett, Robert
Chen, Guang
Queva, Christophe
Li, Li
Tannheimer, Stacey L.
PLOS ONE, 2017, 12 (02):
[25] Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
Kathleen J. Till
Mariah Abdullah
Tahera Alnassfan
Gallardo Zapata Janet
Thomas Marks
Silvia Coma
David T. Weaver
Jonathan A. Pachter
Andrew R. Pettitt
Joseph R. Slupsky
Scientific Reports, 13
[26] Preliminary Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) in China
Ying, Zhitao
Zhou, Keshu
Li, Lanfang
Li, Wenyu
Yang, Su
Liu, Yun
Gu, Yongen
Zhou, Zisong
Tian, Alex
Song, Yuqin
Zhu, Jun
BLOOD, 2022, 140 : 7470 - 7471
[27] Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Soumerai, Jacob Drobnyk
Pagel, John M.
Jagadeesh, Deepa
Salman, Huda S.
Kenkre, Vaishalee Padgaonkar
Asch, Adam Steven
Stathis, Anastasios
Reddy, Nishitha M.
Iasonos, Alexia
Ghalie, Richard
Zelenetz, Andrew David
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[28] Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL)
Schuster, Stephen J.
Dickinson, Michael
Dreyling, Martin
Martinez-Lopez, Joaquin
Kolstad, Arne
Butler, Jason
Ghosh, Monalisa
Popplewell, Leslie
Chavez, Julio C.
Bachy, Emmanuel
Kato, Koji
Harigae, Hideo
Kersten, Marie Jose
Andreadis, Charalambos
Riedell, Peter
Zia, Aiesha
Morisse, Mony Chenda
Fowler, Nathan Hale
Thieblemont, Catherine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S403 - S404
[29] Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
Phillips, Tycel
Smith, Stephen D.
Jurczak, Wojciech
Robak, Tadeusz
Stevens, Don A.
Farber, Charles M.
Pagel, John M.
Maddocks, Kami
Flinn, Ian
Jedrzejczak, Wieslaw W.
Goy, Andre
Zinzani, Pier Luigi
Zaucha, Jan
Coleman, Morton
Chen, Tianling
Lee, Sun Ku
Liang, Wei
Seto, Anna
Wang, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S317 - S317
[30] Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients With Treatement-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
Phillips, Tycel J.
Smith, Stephen D.
Jurczak, Wojciech
Robak, Tadeusz
Stevens, Don
Farber, Charles M.
Pagel, John M.
Maddocks, Kami J.
Flinn, Ian W.
Jedrzejczak, Wieslaw W.
Goy, Andre
Zinzani, Pier Luigi
Zaucha, Jan
Coleman, Morton
Chen, Tianling
Lee, Sun Ku
Liang, Wei
Seto, Anna
Wang, Michael
BLOOD, 2018, 132

← 1 2 3 4 5 →